A Novel Duplication Confirms the Involvement of 5Q23.2 in Autosomal Dominant Leukodystrophy
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Parkin Antibody (C-Term) Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP6402B
10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Parkin Antibody (C-term) Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP6402B Specification Parkin Antibody (C-term) - Product Information Application IF, WB, IHC-P, FC,E Primary Accession O60260 Other Accession NP_004553 Reactivity Human, Mouse Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Antigen Region 387-417 Parkin Antibody (C-term) - Additional Information Gene ID 5071 Other Names E3 ubiquitin-protein ligase parkin, 632-, Confocal immunofluorescent analysis of Parkinson juvenile disease protein 2, Parkin Antibody (C-term)(Cat#AP6402b) with Parkinson disease protein 2, PARK2, PRKN NCI-H460 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG Target/Specificity (green).Actin filaments have been labeled This Parkin antibody is generated from with Alexa Fluor 555 phalloidin (red).DAPI rabbits immunized with a KLH conjugated was used to stain the cell nuclear (blue). synthetic peptide between 387-417 amino acids from the C-terminal region of human Parkin. Dilution IF~~1:10~50 WB~~1:1000 IHC-P~~1:50~100 FC~~1:10~50 Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C Park2 Antibody (C-term) (Cat. #AP6402b) in small aliquots to prevent freeze-thaw western blot analysis in K562 cell line lysates cycles. (35ug/lane).This demonstrates the Park2 antibody detected the Park2 protein (arrow). -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen
CLINICAL RESEARCH www.jasn.org Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen Rany M. Salem ,1 Jennifer N. Todd,2,3,4 Niina Sandholm ,5,6,7 Joanne B. Cole ,2,3,4 Wei-Min Chen,8 Darrell Andrews,9 Marcus G. Pezzolesi,10 Paul M. McKeigue,11 Linda T. Hiraki,12 Chengxiang Qiu,13 Viji Nair,14 Chen Di Liao,12 Jing Jing Cao,12 Erkka Valo ,5,6,7 Suna Onengut-Gumuscu,8 Adam M. Smiles,15 Stuart J. McGurnaghan,16 Jani K. Haukka,5,6,7 Valma Harjutsalo,5,6,7,17 Eoin P. Brennan,9 Natalie van Zuydam,18,19 Emma Ahlqvist,20 Ross Doyle,9 Tarunveer S. Ahluwalia ,21 Maria Lajer,21 Maria F. Hughes,9 Jihwan Park,13 Jan Skupien,15 Athina Spiliopoulou,11 Andrew Liu,22 Rajasree Menon,14,23 Carine M. Boustany-Kari,24 Hyun M. Kang,23,25 Robert G. Nelson,26 Ronald Klein,27 Barbara E. Klein,27 Kristine E. Lee ,27 Xiaoyu Gao,28 Michael Mauer,29 Silvia Maestroni,30 Maria Luiza Caramori,29 Ian H. de Boer ,31 Rachel G. Miller,32 Jingchuan Guo ,32 Andrew P. Boright,12 David Tregouet,33,34 Beata Gyorgy,33,34 Janet K. Snell-Bergeon,35 David M. Maahs,36 Shelley B. Bull ,37 Angelo J. Canty,38 Colin N.A. Palmer,39 Lars Stechemesser,40 Bernhard Paulweber,40 Raimund Weitgasser,40,41 Jelizaveta Sokolovska,42 Vita Rovıte,43 Valdis Pırags, 42,44 Edita Prakapiene,45 Lina Radzeviciene,46 Rasa Verkauskiene,46 Nicolae Mircea Panduru,6,47 Leif C. -
Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades. -
Brain Region-Specific Gene Signatures Revealed by Distinct Astrocyte Subpopulations Unveil Links to Glioma and Neurodegenerative
New Research Disorders of the Nervous System Brain Region-Specific Gene Signatures Revealed by Distinct Astrocyte Subpopulations Unveil Links to Glioma and Neurodegenerative Diseases Raquel Cuevas-Diaz Duran,1,2,3 Chih-Yen Wang,4 Hui Zheng,5,6,7 Benjamin Deneen,8,9,10,11 and Jia Qian Wu1,2 https://doi.org/10.1523/ENEURO.0288-18.2019 1The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas 77030, 2Center for Stem Cell and Regenerative Medicine, UT Brown Foundation Institute of Molecular Medicine, Houston, Texas 77030, 3Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey NL 64710, Mexico, 4Department of Life Sciences, National Cheng Kung University, Tainan City 70101, Taiwan, 5Huffington Center on Aging, 6Medical Scientist Training Program, 7Department of Molecular and Human Genetics, 8Center for Cell and Gene Therapy, 9Department of Neuroscience, 10Neurological Research Institute at Texas’ Children’s Hospital, and 11Program in Developmental Biology, Baylor College of Medicine, Houston, Texas 77030 Abstract Currently, there are no effective treatments for glioma or for neurodegenerative diseases because of, in part, our limited understanding of the pathophysiology and cellular heterogeneity of these diseases. Mounting evidence suggests that astrocytes play an active role in the pathogenesis of these diseases by contributing to a diverse range of pathophysiological states. In a previous study, five molecularly distinct astrocyte subpopulations from three different brain regions were identified. To further delineate the underlying diversity of these populations, we obtained mouse brain region-specific gene signatures for both protein-coding and long non-coding RNA and found that these astrocyte subpopulations are endowed with unique molecular signatures across diverse brain regions. -
Reading Through the Building Blocks of the Genome: Exonic Variation in PD
UNIVERSITY OF CATANIA INTERNATIONAL PhD PROGRAM IN NEUROSCIENCE XXIX Cycle VALENTINA LA COGNATA READING THROUGH THE BUILDING BLOCKS OF THE GENOME: EXONIC VARIATION IN PARKINSON'S DISEASE PhD Thesis Coordinator: Supervisors: Prof. Salvatore Salomone Prof. Velia D’Agata Dr. Sebastiano Cavallaro January 2017 Copyright © V. La Cognata, 2017 All rights reserved. No part of this book may be reproduced, stored in a retrieval system or transmitted in any form or by any means, without prior permission of the author. The copyright of the published papers remains with the publishers. SUMMARY Abstract ...................................................................................................... 5 Chapter 1 .................................................................................................... 7 PARKINSON’S DISEASE ....................................................................................................... 9 HAS EXONIC VARIATION A ROLE IN PD? ............................................................................12 AIMS OF THE PhD WORK ...................................................................................................13 Chapter 2 .................................................................................................. 15 ABSTRACT ........................................................................................................................17 INTRODUCTION ................................................................................................................18 CNVs: A PREVALENT -
Subgroup-Specific Structural Variation Across 1,000 Medulloblastoma Genomes
ARTICLE doi:10.1038/nature11327 Subgroup-specific structural variation across 1,000 medulloblastoma genomes A list of authors and their affiliations appears at the end of the paper Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, with at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas. SCNAs are common in medulloblastoma, and are predominantly subgroup-enriched. The most common region of focal copy number gain is a tandem duplication of SNCAIP, a gene associated with Parkinson’s disease, which is exquisitely restricted to Group 4a. Recurrent translocations of PVT1, including PVT1-MYC and PVT1-NDRG1, that arise through chromothripsis are restricted to Group 3. Numerous targetable SCNAs, including recurrent events targeting TGF-b signalling in Group 3, and NF-kB signalling in Group 4, suggest future avenues for rational, targeted therapy. Brain tumours are the most common cause of childhood oncological Twenty-eight regions of recurrent high-level amplification (copy death, and medulloblastoma is the most common malignant paediatric number $ 5) were identified (Fig. 1d and Supplementary Table 7). brain tumour. Current medulloblastoma therapy including surgical The most prevalent amplifications affected members of the MYC resection, whole-brain and spinal cord radiation, and aggressive family with MYCN predominantly amplified in SHH and Group 4, chemotherapy supplemented by bone marrow transplant yields five- MYC in Group 3, and MYCL1 in SHH medulloblastomas. -
Rare Gain of Chromosome 5 in a Supratentorial Hemispheric
Images in… BMJ Case Rep: first published as 10.1136/bcr-2020-234878 on 17 March 2020. Downloaded from Rare gain of chromosome 5 in a supratentorial hemispheric paediatric pilomyxoid astrocytoma Katherine Clark Pehlivan,1 Denise M Malicki,2 Michael L Levy,3 John Ross Crawford4 1Department of Neurosciences, DESCRIPTION University of California San A previously healthy 11- year- old boy presented Diego, San Diego, California, with self- limited recurrent episodes of dizziness, USA disorientation and visual changes with a normal 2Department of Pathology, Rady neurological examination. MRI revealed a well- Children’s Hospital University of California San Diego, San Diego, circumscribed mixed solid/cystic left parieto- California, USA occipital mass (figure 1). He underwent a gross 3Department of Neurosurgery, total resection where neuropathology demonstrated University of California San moderately cellular proliferation of bland bipolar Diego, San Diego, California, process- forming spindle cells in a myxoid back- USA ground with focal angiocentric arrangement, and 4 Department of Neurosciences absence of Rosenthal fibres, consistent with a diag- and Pediatrics, University of nosis of pilomyxoid astrocytoma (PMA) (figure 2). California San Diego, San Diego, DNA- based next- generation sequencing panel California, USA consisting of 397 cancer- related genes (table 1) performed on paraffin- embedded formalin- fixed Correspondence to Figure 2 H&E- stained sections showed a moderately Dr John Ross Crawford; tumour revealed no reportable mutations and cellular proliferation of bland bipolar process- forming jrcrawford@ ucsd. edu variants of unknown significance of PMS1 and spindle cells in a myxoid background with focal RB1. However, chromosomal microarray analysis angiocentric arrangement consistent with a diagnosis of Accepted 4 March 2020 revealed a gain of chromosome 5. -
Identification of Shared and Unique Gene Families Associated with Oral
International Journal of Oral Science (2017) 9, 104–109 OPEN www.nature.com/ijos ORIGINAL ARTICLE Identification of shared and unique gene families associated with oral clefts Noriko Funato and Masataka Nakamura Oral clefts, the most frequent congenital birth defects in humans, are multifactorial disorders caused by genetic and environmental factors. Epidemiological studies point to different etiologies underlying the oral cleft phenotypes, cleft lip (CL), CL and/or palate (CL/P) and cleft palate (CP). More than 350 genes have syndromic and/or nonsyndromic oral cleft associations in humans. Although genes related to genetic disorders associated with oral cleft phenotypes are known, a gap between detecting these associations and interpretation of their biological importance has remained. Here, using a gene ontology analysis approach, we grouped these candidate genes on the basis of different functional categories to gain insight into the genetic etiology of oral clefts. We identified different genetic profiles and found correlations between the functions of gene products and oral cleft phenotypes. Our results indicate inherent differences in the genetic etiologies that underlie oral cleft phenotypes and support epidemiological evidence that genes associated with CL/P are both developmentally and genetically different from CP only, incomplete CP, and submucous CP. The epidemiological differences among cleft phenotypes may reflect differences in the underlying genetic causes. Understanding the different causative etiologies of oral clefts is -
Identification of Significant Genes with Poor Prognosis in Ovarian Cancer Via Bioinformatical Analysis
Feng et al. Journal of Ovarian Research (2019) 12:35 https://doi.org/10.1186/s13048-019-0508-2 RESEARCH Open Access Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis Hao Feng1†, Zhong-Yi Gu2†, Qin Li2, Qiong-Hua Liu3, Xiao-Yu Yang4* and Jun-Jie Zhang2* Abstract Ovarian cancer (OC) is the highest frequent malignant gynecologic tumor with very complicated pathogenesis. The purpose of the present academic work was to identify significant genes with poor outcome and their underlying mechanisms. Gene expression profiles of GSE36668, GSE14407 and GSE18520 were available from GEO database. There are 69 OC tissues and 26 normal tissues in the three profile datasets. Differentially expressed genes (DEGs) between OC tissues and normal ovarian (OV) tissues were picked out by GEO2R tool and Venn diagram software. Next, we made use of the Database for Annotation, Visualization and Integrated Discovery (DAVID) to analyze Kyoto Encyclopedia of Gene and Genome (KEGG) pathway and gene ontology (GO). Then protein-protein interaction (PPI) of these DEGs was visualized by Cytoscape with Search Tool for the Retrieval of Interacting Genes (STRING). There were total of 216 consistently expressed genes in the three datasets, including 110 up-regulated genes enriched in cell division, sister chromatid cohesion, mitotic nuclear division, regulation of cell cycle, protein localization to kinetochore, cell proliferation and Cell cycle, progesterone-mediated oocyte maturation and p53 signaling pathway, while 106 down-regulated genes enriched in palate development, blood coagulation, positive regulation of transcription from RNA polymerase II promoter, axonogenesis, receptor internalization, negative regulation of transcription from RNA polymerase II promoter and no significant signaling pathways. -
Regulation of Muscle Stem Cell Function by the Transcription Factor Pax7
Regulation of Muscle Stem Cell Function by the Transcription Factor Pax7 Alessandra Pasut Thesis submitted to the Faculty of Graduate and Postdoctoral Studies in partial fulfillment of the requirements for the Doctorate in Philosophy degree in Cellular and Molecular Medicine Department of Cellular and Molecular Medicine Faculty of Medicine University of Ottawa © Alessandra Pasut, Ottawa, Canada, 2015 ...above all don’t fear difficult moments, the best comes out from them. [Rita Levi Montalcini-Nobel laureate, 1909-2012] ii Abstract Pax7 is a paired box transcription factor expressed by all satellite cells which are critically required for muscle regeneration and growth. The absolute requirements of Pax7 in the maintenance of the satellite cell pool are widely acknowledged. However the mechanisms by which Pax7 executes muscle regeneration or contributes to satellite cell homeostasis remain elusive. We performed cell and molecular analysis of Pax7 null satellite cells to investigate muscle stem cell function. Through genome wide studies, we found that genes involved in cell- cell interactions, regulation of migration, control of lipid metabolism and inhibition of myogenic differentiation were significantly perturbed in Pax7 null satellite cells. Analysis of satellite cells in vitro showed that Pax7 null satellite cells undergo precocious myogenic differentiation and have perturbed expression of genes involved in the Notch signaling pathway. We showed that Notch 1 is a novel Pax7 target gene and by using a genetic approach we demonstrate that ectopic expression of the constitutively active intracellular domain of Notch1 (NICD1) in Pax7 null satellite cells is sufficient to maintain the satellite cell pool as well as to restore their proliferation. -
A Genomic Approach to Delineating the Occurrence of Scoliosis in Arthrogryposis Multiplex Congenita
G C A T T A C G G C A T genes Article A Genomic Approach to Delineating the Occurrence of Scoliosis in Arthrogryposis Multiplex Congenita Xenia Latypova 1, Stefan Giovanni Creadore 2, Noémi Dahan-Oliel 3,4, Anxhela Gjyshi Gustafson 2, Steven Wei-Hung Hwang 5, Tanya Bedard 6, Kamran Shazand 2, Harold J. P. van Bosse 5 , Philip F. Giampietro 7,* and Klaus Dieterich 8,* 1 Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, 38000 Grenoble, France; [email protected] 2 Shriners Hospitals for Children Headquarters, Tampa, FL 33607, USA; [email protected] (S.G.C.); [email protected] (A.G.G.); [email protected] (K.S.) 3 Shriners Hospitals for Children, Montreal, QC H4A 0A9, Canada; [email protected] 4 School of Physical & Occupational Therapy, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada 5 Shriners Hospitals for Children, Philadelphia, PA 19140, USA; [email protected] (S.W.-H.H.); [email protected] (H.J.P.v.B.) 6 Alberta Congenital Anomalies Surveillance System, Alberta Health Services, Edmonton, AB T5J 3E4, Canada; [email protected] 7 Department of Pediatrics, University of Illinois-Chicago, Chicago, IL 60607, USA 8 Institut of Advanced Biosciences, Université Grenoble Alpes, Inserm, U1209, CHU Grenoble Alpes, 38000 Grenoble, France * Correspondence: [email protected] (P.F.G.); [email protected] (K.D.) Citation: Latypova, X.; Creadore, S.G.; Dahan-Oliel, N.; Gustafson, Abstract: Arthrogryposis multiplex congenita (AMC) describes a group of conditions characterized A.G.; Wei-Hung Hwang, S.; Bedard, by the presence of non-progressive congenital contractures in multiple body areas.